The Medicines Company announced positive results for the ORION-9 Phase III clinical study of inclisiran in patients with Heterozygous Familial Hypercholesterolemia.
The Medicines Company announced positive topline results for the ORION-9 Phase III clinical study in patients with Heterozygous Familial Hypercholesterolemia (HeFH). ORION-9 met all primary and secondary endpoints, and inclisiran demonstrated durable and potent efficacy and was well-tolerated with excellent safety that was generally well-balanced between the treatment groups. Furthermore, there were no treatment-related liver or renal laboratory abnormalities. Detailed efficacy, tolerability and safety data from ORION-9 will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Monday, November 18, 9:24am EST, during Late Breaking Science VI: New Frontiers in Lipid Therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.